Replies to post #254115 on Biotech Values

[WorstLuck]

If you investigate you run the risk of failure.
Many big companies have failed- particularly in HCV. (If you wanted an example BMY/Inhibitex) Enanta's was a trifle in comparison.

While true, my sense is that many ENTA investors are rationalizing or otherwise excusing things that are bigger than HBV - which we have both said (in different ways) was NBD.

I made a post about three weeks ago https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175528716 that summarized my view of ENTA's current status. It concluded:

So yeah, $6 looks silly right now. Unless ENTA does something equally silly with their $$$.

That still holds. Price doesn't have to go higher between now and the next RSV readout but generally speaking, there is a limit to how low it can go with an intact balance sheet and there is clearly room to the upside. It's also possible they could partner a pre-clinical asset or make some other deal in the meantime. I'm not bearish ENTA at this price over the next few months, I just think my investments should be somewhere else.